Delhi High Court directs UCB to approach IPAB

Manish Rajan of livemint.com reported that the Delhi High Court on Monday dismissed the petition filed by Global Biopharma major UCB Frachim against the Indian generic major Cipla and the Indian Patent Office over rejection of its patent for a new anti-allergic drug. In its petition, UCB requested the Court to quash the order passed by the Controller General of Patents on July 24, 2009 rejecting its claims. The High Court directed UCB Farchim to file its appeal before the Intellectual Property Appellate Board instead of a High Court. However, still we are not sure which drug and patent application is subject of dispute. Even the Indian Patent Office does not have the Controller decision uploaded on the IPIRS database.